Income Statement (Annual)
ARLP / Alliance Resource Partners, L.P. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000 except per share units.
|Operating Costs And Expenses|
|Cost Of Goods Sold Excluding Depreciation Depletion And Amortization||797,527||1,009,935||1,131,750||1,303,291||1,398,763||1,383,360||1,377,053||1,138,848||1,095,167|
|Outside Coal Purchases||7,524||17,078||54,280||38,607||2,030||14||327||1,514||-|
|General And Administrative Expense||41,117||50,818||52,334||58,737||63,697||72,552||67,484||72,529||61,760|
|Depreciation Depletion And Amortization||117,524||146,881||160,335||218,122||264,911||274,566||333,713||322,509||268,981|
|Gain Loss Related To Litigation Settlement||-||-||-||-||-||-||-||-||-|
|Costs And Expenses||1,009,425||1,258,296||1,430,638||1,659,822||1,762,043||1,756,513||1,912,304||1,565,511||1,467,608|
|Operating Income Loss||221,606||351,769||412,922||374,479||443,518||544,208||361,429||365,942||328,612|
|Investment Income Interest||1,049||200||375||229||962||1,671||1,459||10||94|
|Income Loss From Equity Method Investments||-||-||-3,404||-14,650||-24,441||-16,648||-49,046||3,543||13,860|
|Investment Income Dividend||-||-||-||-||-||-||-||-||6,398|
|Other Nonoperating Income Expense||-||-||-||-||-||-||-||-||-|
|Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest||-||322,758||388,922||334,489||394,886||497,213||306,192||339,551||304,411|
|Income Tax Expense Benefit||708||1,741||-431||-1,082||1,396||-||21||13||210|
|Net Income Loss Attributable To Noncontrolling Interest||190||-||-||-||-||-16||-27||140||563|
|Net Income Loss||192,157||321,017||389,353||335,571||393,490||497,229||306,198||339,398||303,638|
|Net Income Loss Allocated To General Partners||60,639||-73,172||86,251||-106,837||-121,349||-138,274||146,338||80,911||21,904|
|Net Income Loss Allocated To Limited Partners||131,518||247,845||303,102||228,734||272,141||358,955||159,860||258,487||281,734|
|Net Income Loss Per Outstanding Limited Partnership Unit Basic Net Of Tax||-||-||-||-||0||0||0||0||0|
|Net Income Loss Net Of Tax Per Outstanding Limited Partnership Unit Diluted||-||-||-||-||0||0||0||0||0|
|Distributions Per Limited Partnership Unit Outstanding||0||0||0||0||0||0||0||0||0|
|Weighted Average Limited Partnership Units Outstanding||-||-||-||-||73,904||74,044||74,174||74,354||98,708|
|Weighted Average Limited Partnership Units Outstanding Diluted||-||-||-||-||73,904||74,044||74,174||74,354||98,708|
Peers - Bituminous Coal and Lignite Surface Mining (1221)
ACIIQ / Arch Coal, Inc.
AHGP / Alliance Holdings GP, L.P
ANRZQ / Alpha Natural Resources, Inc.
ARCH / Arch Coal, Inc.
BTU / Peabody Energy Corporation
BTUUQ / Peabody Energy Corp.
CERX / Colombia Energy Resources, Inc.
CLD / Cloud Peak Energy Inc.
CLDEP / Cloud Peak Energy Inc.
CNX.WI / CNX Resources Corporation
JRCCQ / James River Coal Co.
NRP / Natural Resource Partners L.P.
RHNO / Rhino Resource Partners LP
RNO / Rhino Resource Partners LP
ROYE / Royal Energy Resources, Inc.
WLB / Westmoreland Coal Co.
WLBA / WESTMORELAND COAL CO
WMLP / Westmoreland Resource Partners, LP
8h - Asif
Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
as of ET